All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

DONATE

Brought to you by

Scientific Education Support logo

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.

SubtypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2018-06-08T10:37:21.000Z

Francine Foss | ASCO 2018 | Novel therapies for CTCL

By Sara Valente, Claire Baker
Featured
Francine Foss
Jun 8, 2018
Share:

Bookmark this article

ASCO Annual Meeting, 1-5 June 2018, Chicago, IL
Francine Foss
Yale Cancer Center, New Haven, US

Interview topic: Novel therapies for CTCL

Francine Foss | ASCO 2018 | Novel therapies for CTCL

More about...
ASCO 2018Brentuximab vedotinCobomarsenCutaneous T-cell lymphomaMature T and NK cell neoplasmsMogamulizumabMycosis fungoidesSézary syndrome

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
41 votes - 80 days left ...

Related articles

Add bookmark

The efficacy and safety of mogamulizumab for advanced mycosis fungoides and Sézary syndrome

A review of mogamulizumab safety and efficacy by Daniel Lewis and Alain Rook was recently published in Expert Review of Anticancer Therapy.

Jun 11, 2020
Add bookmark

The efficacy and safety of mogamulizumab for advanced mycosis fungoides and Sézary syndrome

A review of mogamulizumab safety and efficacy by Daniel Lewis and Alain Rook was recently published in...

Jun 11, 2020
Add bookmark

Prof. Miles Prince | ASH 2017 | Updated analysis of the ALCANZA Trial

59th ASH Annual Meeting and Exposition, 9 - 12 Dec 2017, Atlanta, GA Professor Miles Prince Peter MacCallum Cancer Centre, Victoria, AU Topic: Updated analysis of the ALCANZA...

Dec 22, 2017
Add bookmark

Prof. Miles Prince | ASH 2017 | Updated analysis of the ALCANZA Trial

59th ASH Annual Meeting and Exposition, 9 - 12 Dec 2017, Atlanta, GA Professor Miles Prince Peter MacCallum Cancer Centre,...

Dec 22, 2017

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox